Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Time to Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-strong trading volume on Thursday. Approximately 369,784 shares were traded during mid-day trading, an increase of 278% from the average daily volume of 97,781 shares. The stock last traded at $29.9580 and had previously closed at $29.70.

Analyst Ratings Changes

NBTX has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Guggenheim started coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Price Performance

The company has a fifty day moving average price of $31.76 and a 200-day moving average price of $33.84.

About Nanobiotix

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.